阿托伐他汀钙片联合布地奈德福莫特罗吸入粉雾剂治疗慢性阻塞性肺疾病的临床疗效及对患者血气分析指标的影响

Clinical Efficacy of Atorvastatin Calcium Tablets Combined with Budesonide and Formoterol Fumarate Powder for Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease and its Influence on Blood GasA nalysis Parameters

目的:探讨阿托伐他汀钙片联合布地奈德福莫特罗吸入粉雾剂治疗慢性阻塞性肺疾病(COPD)患者的临床疗效,及对患者血气分析指标的影响。方法:选取2021年12月~2023年12月期间某院收治的120例COPD患者作为研究对象,按照随机数字表法分为对照组和观察组,每组60例。对照组患者给予布地奈德福莫特罗吸入粉雾剂(Ⅱ)治疗,观察组在对照组治疗基础上加用阿托伐他汀钙片,两组均连续治疗4周。比较两组患者临床疗效、肺功能[用力肺活量(FVC)、呼气流量峰值(PEF)和第1秒用力呼气容积/用力肺活量(FEV1/FVC)]、血气分析指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))和血氧饱和度(SO_(2))]、辅助性T细胞1/辅助性T细胞2(Th1/Th2)、辅助性T细胞17/调节性T细胞(Th17/Treg)及不良反应发生情况。结果:治疗后,观察组患者治疗总有效率(93.33%)高于对照组(75.00%,P<0.05)。两组患者FVC、PEF及FEV1/FVC均升高(P<0.05),且观察组高于对照组(P<0.05);两组患者PaO_(2)、SO_(2)均升高(P<0.05),且观察组高于对照组(P<0.05);两组患者PaCO_(2)均降低(P<0.05),且观察组低于对照组(P<0.05);两组患者Th1/Th2和Th17/Treg均降低(P<0.05),且观察组低于对照组(P<0.05)。两组患者不良反应总发生率比较无统计学差异(P>0.05)。结论:与单用布地奈德福莫特罗吸入粉雾剂相比,阿托伐他汀钙片联合布地奈德福莫特罗吸入粉雾剂治疗COPD的临床疗效更佳,可有效改善患者肺功能、血气分析指标,且未增加不良反应的发生风险。

Objective:To explore the clinical efficacy of atorvastatin calcium tablets combined with budesonide and formoterol fumarate powder for inhalation in patients with chronic obstructive pulmonary disease(COPD)and its effects on blood gas analysis parameters.Methods:A total of 120 COPD patients admitted to a hospital from December 2021 to December 2023 were selected as subjects and divided into the control group and the observation group using random number table method,with 60 cases in each group.The control group were treated with budesonide and formoterol fumarate powder for inhalation(Ⅱ),and the observation group were treated with atorvastatin calcium tablets in addition to the treatment of the control group,and both groups were treated continuously for 4 weeks.The clinical efficacy,pulmonary function[forced vital capacity(FVC),peak expiratory flow(PEF)and forced expiratory volume in one second to forced vital capacity(FEV1/FVC)],blood gas analysis parameters[arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2))and blood oxygen saturation(SO_(2))],the ratio of helper T cell 1/helper T cell 2(Th1/Th2)and the ratio of helper T cell 17/regulatory T cell(Th17/Treg),and the occurrence of adverse reactions were compared between the two groups.Results:Following treatment,the overall response rate of the observation group(93.33%)was higher than that of the control group(75.00%,P<0.05).FVC,PEF,and FEV1/FVC increased in both groups(P<0.05),with higher results in the observation group(P<0.05);PaO_(2)and SO_(2)increased in both groups(P<0.05),with higher results in the observation group(P<0.05);PaCO_(2)decreased in both groups(P<0.05),with lower results in the observation group(P<0.05);Th1/Th2 and Th17/Treg ratios decreased in both groups(P<0.05),with lower ratios in the observation group(P<0.05).The overall incidence of adverse reactions showed no statistically significant difference between the two groups(P>0.05).Conclusion:Better clinical efficacy can be expected with combination treatment of atorvastatin calcium tablets and budesonide and formoterol fumarate powder for inhalation in the treatment of COPD than single budesonide and formoterol fumarate powder for inhalation,which can effectively improve lung function and blood gas analysis parameters in patients with COPD,and does not increase the risk of adverse reactions.